Next Event in the Partnering series

Accelerate licensing and collaboration deals across TAC and Molecular Glue discovery platforms and pipelines to validate capabilities, improve tissue specificity of protein homeostasis, and leverage known, undruggable targets across diseases.

view agenda

Thank you to our speakers, sponsors, and delegates who joined us in January for the summit! If you are interested in the 2026 event, please get in touch at info@hansonwade.com.

Fast-Track Rational & Structure-Based Molecular Glues from Discovery to Clinic by Improving PPI Prediction, Hit Discovery & Lead Optimization Whilst Overcoming PKPD & Toxicity Challenges to Finally Drug the Undruggable

57705 Website Banner 47392 (1200 x 307 px) (1)

2025 EVENT GUIDE

PARTNER

Welcome to the 3rd Molecular Glue Drug Development Summit

Pioneering Rationally Designed Molecular Glue Degraders for Clinical Application

Molecular glue development continues to thrive, offering exciting opportunities to target previously undruggable proteins and treat a wide range of diseases. 2024 saw a multitude of collaborations, with Takeda and Degron Therapeutics entering a deal worth $1.2 billion.

The 3^rd Molecular Glue Drug Development Summit returned as the only industry-dedicated forum bringing together 90+ experts as they showcased the latest advancements and breakthroughs in molecular glue drug development through discussions and data-driven case studies on screening tools, novel mechanisms of actions of proximity-based degrading and non-degrading molecular glues and lead optimization strategies, to streamline discovery and development of safe and effective glues.